RheumaGen, an Aurora, CO-based cell and gene remedy firm, raised $15M in Sequence A funding.
The spherical was led by SPRIM World Investments and William Taylor Nominees.
The corporate intends to make use of the funds to assist the Part I medical trial of its lead program, RG0401, for treatment-resistant or refractory rheumatoid arthritis (RA).
Led by CEO Richard Freed and CSO Dr. Brian Freed, RheumaGen is creating a category of cell and gene therapies designed to treatment autoimmune ailments at their supply. It’s targeted on modifying the human leukocyte antigen (HLA), or “immune gene,” in order that the immune system doesn’t assault wholesome cells.
RG0401, its lead program, targets 10-20% of RA sufferers who’re refractory or treatment-resistant and endure substantial unmet want. The corporate is at the moment conducting RG0401 IND-enabling research and plans to start the Part I medical trial in 2026. it goals to treatment refractory RA by treating its HLA supply.
With a precision edit to a DNA marker(s) of the HLA gene, RG0401 is designed solely to make a affected person’s HLA molecules mirror these of an individual immune to RA, whereas sustaining the remainder of the immune system as regular. This remedy adjustments dangerous HLA alleles to wholesome ones and prevents T cells from activating continual autoimmune responses, thereby halting not solely cell and tissue degradation but additionally the complete illness course of with this strategy.
FinSMEs
10/01/2025
